Clinical trial
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate…
NCT00248157 · Novartis Pharmaceuticals, Industry · Terminated
Key facts
| NCT number | NCT00248157 |
|---|---|
| Title | Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy |
| Official title | An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Octreotide Acetate in Microspheres in the Therapy of Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy (NPDR) or Low Risk Proliferative Diabetic Retinopathy (PDR) |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetic Retinopathy |
| Intervention type | Drug |
| Interventions | Octreotide acetate in microspheres |
| Enrollment | 105 |
| Start date | Nov 1, 2005 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Nov 3, 2005 |
| Last update posted | May 1, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: